1-14 of 14
Daniel Jones
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Mutational profile in previously treated patients with chronic lymphocytic leukemia progression on acalabrutinib or ibrutinib

Clinical Trials & Observations
Jennifer A. Woyach, Daniel Jones, Wojciech Jurczak, Tadeusz Robak, Árpád Illés, Arnon P. Kater, Paolo Ghia, John C. Byrd, John F. Seymour, Susan Long, Nehad Mohamed, Samon Benrashid, Tzung-Huei Lai, Gary De Jesus, Richard Lai, Gerjan de Bruin, Simon Rule, Veerendra Munugalavadla
Journal: Blood
Blood (2024) 144 (10): 1061–1068.
https://doi.org/10.1182/blood.2023023659
Published: 2024
Includes: Supplemental data
Journal Articles

Characterizing the Development of Secondary Myelodysplastic Syndrome (MDS) with Antecedent or Concurrent Chronic Lymphocytic Leukemia (CLL) in the Era of Small Molecule Inhibitors for the Treatment of CLL

Kristin L Koenig, Prachi Jain, Ying Huang, Kerry A. Rogers, Seema A. Bhat, Jennifer A. Woyach, Michael R. Grever, Uma Borate, Alice S. Mims, Daniel Jones, Cecelia Miller, James S. Blachly, Adam S Kittai
Journal: Blood
Blood (2022) 140 (Supplement 1): 4071–4073.
https://doi.org/10.1182/blood-2022-168274
Published: 2022
Journal Articles

FISH Analysis of CDKN2A/B Deletion in Chronic Lymphocytic Leukemia

Samantha M Teierle, Ying Huang, Adam S Kittai, Seema A. Bhat, Michael R. Grever, Kerry A. Rogers, Weiqiang Zhao, Daniel Jones, John C. Byrd, Matthew R Avenarius, Nyla A. Heerema, Jennifer A. Woyach, Cecelia Miller
Journal: Blood
Blood (2022) 140 (Supplement 1): 7016–7017.
https://doi.org/10.1182/blood-2022-163753
Published: 2022
Journal Articles

Impact of Circulating Lymphoma at Diagnosis on Outcomes in Patients with Marginal Zone Lymphoma

Kaitlin Annunzio, Natalie S. Grover, Rui Li, Daniel Jones, Walter Hanel, Beth Christian, Adam J. Olszewski, Narendranath Epperla
Journal: Blood
Blood (2022) 140 (Supplement 1): 3644–3645.
https://doi.org/10.1182/blood-2022-164892
Published: 2022
Journal Articles

Impact of Circulating Lymphoma at Diagnosis on Outcomes in Patients with Diffuse Large B-Cell Lymphoma

Srichandhana Rajamouli, Eric McLaughlin, Walter Hanel, David A. Bond, Yazeed Sawalha, Timothy J. Voorhees, Lapo Alinari, Lalit Sehgal, Kami J. Maddocks, Beth Christian, Daniel Jones, Narendranath Epperla
Journal: Blood
Blood (2022) 140 (Supplement 1): 6659–6660.
https://doi.org/10.1182/blood-2022-166988
Published: 2022
Journal Articles

Comparative Outcomes and Molecular Response Predictors of IDH1/2-Mutated Adult Acute Myeloid Leukemia (AML) Patients (Pts) after Frontline Treatment with Intensive Induction Chemotherapy (IC), Targeted Inhibitors, or Hypomethylating Agents (HMA) (Alliance)

Uma Borate, Prapti A. Patel, Chetasi Talati, Jessica Kohlschmidt, Michael P. Ozga, Yazan F. Madanat, Luke Fletcher, Ravi Patel, Krzysztof Mrózek, Deedra Nicolet, Akriti G Jain, Virginia Olivia Volpe, Fei Yang, Richard D. Press, Daniel Jones, James S. Blachly, Christopher J. Walker, Andrew J Carroll, Guido Marcucci, Maria R. Baer, William Blum, Bayard L. Powell, Jonathan E Kolitz, Richard A. Larson, Richard M. Stone, John C. Byrd, Alice S. Mims, Kendra Sweet, Ann-Kathrin Eisfeld
Journal: Blood
Blood (2021) 138 (Supplement 1): 226.
https://doi.org/10.1182/blood-2021-152838
Published: 2021
Journal Articles

Phase 2 study of ibrutinib in classic and variant hairy cell leukemia

Clinical Trials & Observations
Kerry A. Rogers, Leslie A. Andritsos, Lai Wei, Eric M. McLaughlin, Amy S. Ruppert, Mirela Anghelina, James S. Blachly, Timothy Call, Dai Chihara, Anees Dauki, Ling Guo, S. Percy Ivy, Lacey R. James, Daniel Jones, Robert J. Kreitman, Gerard Lozanski, David M. Lucas, Apollinaire Ngankeu, Mitch Phelps, Farhad Ravandi, Charles A. Schiffer, William E. Carson, III, Jeffrey A. Jones, Michael R. Grever
Journal: Blood
Blood (2021) 137 (25): 3473–3483.
https://doi.org/10.1182/blood.2020009688
Published: 2021
Includes: Supplemental data
Journal Articles

Rarity of B-Cell Receptor Pathway Mutations in Progression-Free Patients With Chronic Lymphocytic Leukemia (CLL) During First-Line Versus Relapsed/Refractory (R/R) Treatment With Ibrutinib

Adrian Wiestner, MD PhD, Paolo Ghia, MD PhD, John C. Byrd, MD, Inhye E Ahn, MD, Carol Moreno, MD PhD, Susan M. O'Brien, MD, Daniel Jones, MD PhD, Leo W. K. Cheung, PhD, Elizabeth Chong, PhD, Kevin Kwei, PhD, James P. Dean, MD PhD, Danelle F. James, MD MAS, Jennifer A. Woyach, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 32–33.
https://doi.org/10.1182/blood-2020-134386
Published: 2020
Journal Articles

Outcomes of IDH1 - and IDH2 -Mutated AML Patients Undergoing Allogeneic Hematopoietic Cell Transplantation

Evan C. Chen, MD, Shuli Li, PhD, Ann-Kathrin Eisfeld, MD, Marlise R Luskin, MDMS, Alice S. Mims, MD, Daniel Jones, MD PhD, Joseph H. Antin, MD, Corey Cutler, MD MPH, FRCPC, John Koreth, MBBS, DPhil, Vincent T. Ho, MD, Mahasweta Gooptu, MD, Rizwan Romee, MD, Areej El-Jawahri, MD, Steven L. McAfee, MD, Zachariah Defilipp, MD, Robert J. Soiffer, MD, Yi-Bin Chen, MD, Amir T. Fathi
Journal: Blood
Blood (2020) 136 (Supplement 1): 2–3.
https://doi.org/10.1182/blood-2020-140353
Published: 2020
Journal Articles

the Development and Expansion of Resistant Subclones Precedes Relapse during Ibrutinib Therapy in Patients with CLL

Jennifer A. Woyach, MD, Daphne Guinn, PhD, Amy S. Ruppert, MAS, James S. Blachly, MD, Arletta Lozanski, MS, Nyla A. Heerema, PhD, Weiqiang Zhao, MD PhD, Joshua Coleman, MD, Daniel Jones, Lynne V. Abruzzo, MD PhD, Amber Gordon, MLS, Rose Mantel, Lisa L. Smith, MS, Samantha McWhorter, Melanie Davis, PhD, Tzyy-Jye Doong, PhD, Fan Ny, CNP, Margaret S. Lucas, PA-C, Weihong Chase, CNP, Jeffrey Jones, MD MPH, Joseph M. Flynn, DO, MPH, Kami J. Maddocks, MD, Samantha Jaglowski, MD MPH, Leslie A. Andritsos, MD, Farrukh T. Awan, Kristie Blum, MD, Michael R. Grever, MD, Gerard Lozanski, MD, John C. Byrd, MD, Amy J. Johnson, PhD
Journal: Blood
Blood (2016) 128 (22): 55.
https://doi.org/10.1182/blood.V128.22.55.55
Published: 2016
Journal Articles

Long-term outcome of patients with chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors after imatinib failure is predicted by the in vitro sensitivity of BCR-ABL kinase domain mutations

Clinical Trials & Observations
Elias Jabbour, Daniel Jones, Hagop M. Kantarjian, Susan O'Brien, Constantine Tam, Charles Koller, Jan A. Burger, Gautam Borthakur, William G. Wierda, Jorge Cortes
Journal: Blood
Blood (2009) 114 (10): 2037–2043.
https://doi.org/10.1182/blood-2009-01-197715
Published: 2009
Journal Articles

All-Trans Retinoic Acid (ATRA) and Arsenic Trioxide (As 2 O 3 ) Combination Therapy Induces High Rates of Durable Molecular Remission in Newly Diagnosed Acute Promyelocytic Leukemia (APL).

Apostolia-Maria Tsimberidou, MD, PhD, Hagop Kantarjian, MD, Susan O’Brien, MD, Guillermo Garcia-Manero, MD, Charles Koller, MD, Daniel Jones, MD, Sherry Pierce, RN, Mark Brandt, BA, Michael Keating, MB, BS, Estey Estey, MD
Journal: Blood
Blood (2007) 110 (11): 1834.
https://doi.org/10.1182/blood.V110.11.1834.1834
Published: 2007
Journal Articles

Survival benefit with imatinib mesylate versus interferon-α–based regimens in newly diagnosed chronic-phase chronic myelogenous leukemia

Clinical Trials & Observations
Hagop M. Kantarjian, Moshe Talpaz, Susan O'Brien, Daniel Jones, Francis Giles, Guillermo Garcia-Manero, Stefan Faderl, Farhad Ravandi, Mary Beth Rios, Jianqin Shan, Jorge Cortes
Journal: Blood
Blood (2006) 108 (6): 1835–1840.
https://doi.org/10.1182/blood-2006-02-004325
Published: 2006
Journal Articles

High frequency of NPM1 gene mutations in acute myeloid leukemia with prominent nuclear invaginations (“cuplike” nuclei)

Weina Chen, Georgios Z. Rassidakis, Jiang Li, Mark Routbort, Daniel Jones, Hagop Kantarjian, L. Jeffrey Medeiros, Carlos E. Bueso-Ramos
Journal: Blood
Blood (2006) 108 (5): 1783–1784.
https://doi.org/10.1182/blood-2006-03-014340
Published: 2006